ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 954

Diagnosis of Secondary Fibromyalgia in an Established Rheumatoid Arthritis Cohort

Yvonne C. Lee1, Christine K. Iannaccone1, Michelle A. Frits1, M. Weinblatt2 and Nancy A. Shadick3, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, 3Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Fatigue, fibromyalgia, pain, physical function and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Fibromyalgia and Soft Tissue Disorders

Session Type: Abstract Submissions (ACR)

Background/Purpose: The prevalence of fibromyalgia (FM) is 7-10 times higher among rheumatoid arthritis (RA) patients than the general population.  However, the diagnosis of FM in RA is difficult because symptoms of FM and RA overlap.  Different methods of assessing FM in RA have been suggested, including using the Multidimensional Health Assessment Questionnaire (MDHAQ) pain/physical function ratio, MDHAQ fatigue/physical function ratio and the difference between tender joint count and swollen joint count.  We applied these methods and the 2010 American College of Rheumatology (ACR) Diagnostic Criteria for FM to a cohort of RA patients.  We examined the association between inflammation and the diagnosis of FM to determine which methods were most affected by inflammatory disease activity.

Methods: Our study population included 207 RA patients at an academic medical center.  RA disease activity was assessed via joint examinations and C-reactive protein (CRP).  To determine whether participants met the 2010 ACR Diagnostic Criteria for FM, participants completed the Widespread Pain Index and a combination of questions about cognitive and somatic symptoms.  Participants also completed the MDHAQ.  Four definitions of FM were assessed: 1) MDHAQ pain/physical function ≥ 5, 2) MDHAQ fatigue/physical function ≥ 5, 3) tender joint count – swollen joint count ≥ 7, and 4) the ACR 2010 Diagnostic Criteria for FM.  Multivariable associations were assessed using logistic regression models.

Results:   The prevalence of FM varied from 12.6% to 23.7% depending on which FM definition was used.  A difference of ≥ 7 between the tender joint count and swollen joint count was the most conservative measure, whereas a MDHAQ fatigue/physical function ratio ≥ 5 was most permissive.  The diagnosis of FM based on MDHAQ pain/physical function ratios was most significantly associated with CRP ≥ 3 (OR 5.2, 95% CI 1.6-17.7) and swollen joint count ≥ 1 (OR 4.5, 95% CI 1.1-18.1), whereas the diagnosis of FM based on the ACR 2010 Diagnostic Criteria was most significantly associated with depression (OR 3.9, 95% CI 1.2-12.8) (Table).

Conclusion:  Depending on the definition of FM, the relationship between inflammation and FM diagnosis varies.  The ACR 2010 Diagnostic Criteria for FM and the difference between tender joint count and swollen joint count are less correlated with inflammation than the MDHAQ pain/physical function and fatigue/physical function ratios. Future studies are necessary to determine the validity of these measures compared with physician diagnosis of FM.

Table.  Multivariable-adjusted associations between clinical variables and diagnosis of secondary fibromyalgia based on: 1) MDHAQ pain/physical function, 2) MDHAQ fatigue/physical function, 3) tender joint count – swollen joint count, and 4) ACR 2010 Diagnostic Criteria for Fibromyalgia.*

Clinical Variable

Fibromyalgia Definition

MDHAQ Pain/Physical Function ≥ 5

MDHAQ Fatigue/Physical Function ≥ 5

Tender Joint Count – Swollen Joint Count ≥ 7

ACR 2010 Diagnostic Criteria for Fibromyalgia

OR (95% CI)

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

OR (95% CI)

P-value

Inflammatory Variables

 

 

 

 

 

 

 

 

C-reactive protein ≥ 3.0 mg/dl

5.3 (1.6-17.7)

0.007

2.7 (1.0-7.4)

0.05

1.6 (0.6-4.2)

0.35

0.6 (0.2-2.0)

0.39

Swollen joint count ≥ 1

4.5 (1.1-18.1)

0.03

1.1 (0.5-2.9)

0.78

0.5 (0.2-1.2)

0.11

0.6 (0.2-1.7)

0.34

Psychosocial Variables

 

 

 

 

 

 

 

 

Medical Outcomes Study Sleep Problems Index > 35

1.4 (0.4-4.6)

0.59

14.1 (5.2-38.5)

<0.0001

1.2 (0.4-3.4)

0.79

3.4 (1.1-10.8)

0.05

Hospital Anxiety and Depression Scale Depression Score ≥ 8

2.6 (0.7-10.2)

0.17

1.3 (0.4-3.9)

0.62

1.3 (0.4-4.3)

0.72

3.9 (1.2-12.8)

0.03

Hospital Anxiety and Depression Scale Anxiety Score ≥ 8

2.0 (0.5-7.3)

0.29

0.9 (0.3-2.6)

0/87

1.5 (0.5-4.9)

0.48

2.0 (0.6-6.3)

0.25

Pain Catastrophizing Scale Score ≥ 15

1.2 (0.3-5.0)

0.76

1.0 (0.3-2.7)

0.93

2.1 (0.7-6.6)

0.19

1.1 (0.3-3.6)

0.92

* Each column is a separate model adjusted for age, gender and all variables listed in the table.


Disclosure:

Y. C. Lee,

Forest Laboratories,

2,

Merck Pharmaceuticals,

1,

Novartis Pharmaceutical Corporation,

1,

Elan Corporation,

1;

C. K. Iannaccone,
None;

M. A. Frits,
None;

M. Weinblatt,

MedImmune,

2,

MedImmune,

5,

Crescendo Biosciences,

2,

Cresendo Biosciences,

5;

N. A. Shadick,

Amgen,

2,

Abbott Immunology Pharmaceuticals,

2,

Genentech and Biogen IDEC Inc.,

2,

Crescendo Bioscience,

2,

Medimmune,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnosis-of-secondary-fibromyalgia-in-an-established-rheumatoid-arthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology